Difamilast

Difamilast (OPA-15406) 是一种局部的，具有选择性的非甾体磷酸二酯酶 4 (PDE4) 抑制剂，对 B 亚型具有特别有效的抑制作用 (IC50=11.2 nM)。Difamilast 可用于研究轻度至中度特应性皮炎 (AD)。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
1mg

￥1175.00

940.00

- +
5mg

￥2900.00

2320.00

- +
10mg

￥4600.00

3680.00

- +
25mg

￥9212.00

7370.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajcx34022
CAS: 937782-05-3
别名: OPA-15406
分子式: C23H24F2N2O5
分子量: 446.44
纯度: >98%
溶解度: DMSO : 100 mg/mL (223.99 mM; Need ultrasonic)
储存: Store at -20°C
库存: 现货

Background

Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD)[1][2][3].

OPA-15406 is highly selective for inhibition of PDE4 subtype B (IC50=11.2 nM), and OPA-15406 also exerts inhibitory effects on PDE2[2].

OPA-1540 improves skin condition in relevant animal models of AD[1].

[1]. Hanifin JM, et, al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016 Aug;75(2):297-305.
[2]. Ahluwalia J, et, al. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs. 2017 Sep;77(13):1389-1397.
[3]. Soeberdt M, et, al. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020 Aug 15;881:173242.